Sana Biotechnology (NASDAQ:SANA) Stock Price Down 5.9% – Should You Sell?

Sana Biotechnology, Inc. (NASDAQ:SANA) fell 5.9% on Monday . The company traded as low as $4.85 and last traded at $4.8250. 1,991,801 shares traded hands during mid-day trading, a decline of 64% from the average session volume of 5,605,642 shares. The stock had previously closed at $5.13.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on SANA shares. Citizens Jmp increased their price objective on Sana Biotechnology from $5.00 to $8.00 and gave the stock a “market outperform” rating in a report on Thursday, October 30th. Wedbush lifted their price target on Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. JMP Securities set a $8.00 target price on shares of Sana Biotechnology in a research note on Thursday, October 30th. Finally, HC Wainwright decreased their target price on shares of Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.33.

Sana Biotechnology Stock Up 13.6%

The company has a 50-day moving average price of $4.46 and a 200-day moving average price of $3.71. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -5.09 and a beta of 1.95.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.03. Equities analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SANA. Nisa Investment Advisors LLC lifted its stake in shares of Sana Biotechnology by 673.8% in the second quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock valued at $30,000 after buying an additional 9,501 shares during the period. Hoey Investments Inc. acquired a new position in Sana Biotechnology in the 2nd quarter valued at approximately $33,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of Sana Biotechnology in the 3rd quarter worth approximately $36,000. TD Waterhouse Canada Inc. acquired a new stake in shares of Sana Biotechnology during the 3rd quarter worth approximately $37,000. Finally, Lyell Wealth Management LP bought a new stake in shares of Sana Biotechnology during the third quarter valued at approximately $37,000. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.